Equities Analysts Offer Predictions for Aprea Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:APRE)

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Investment analysts at Wedbush issued their Q1 2025 EPS estimates for Aprea Therapeutics in a research report issued to clients and investors on Tuesday, March 26th. Wedbush analyst R. Driscoll anticipates that the company will earn ($1.00) per share for the quarter. Wedbush has a “Outperform” rating and a $11.00 price objective on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($1.56) per share. Wedbush also issued estimates for Aprea Therapeutics’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.31) EPS and FY2028 earnings at $0.81 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a report on Tuesday.

Aprea Therapeutics Stock Performance

Aprea Therapeutics stock opened at $6.07 on Thursday. The stock’s fifty day moving average price is $6.36 and its two-hundred day moving average price is $4.99. Aprea Therapeutics has a one year low of $2.78 and a one year high of $8.85.

Institutional Trading of Aprea Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its stake in Aprea Therapeutics by 5.7% in the first quarter. Renaissance Technologies LLC now owns 297,900 shares of the company’s stock valued at $554,000 after purchasing an additional 15,977 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Aprea Therapeutics in the second quarter worth $54,000. BNP Paribas Arbitrage SNC bought a new position in shares of Aprea Therapeutics in the third quarter worth $40,000. Millennium Management LLC increased its stake in Aprea Therapeutics by 35.7% in the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock valued at $53,000 after acquiring an additional 43,293 shares during the last quarter. Finally, Geode Capital Management LLC bought a new position in Aprea Therapeutics in the second quarter valued at $74,000. 34.19% of the stock is owned by institutional investors.

Insider Activity at Aprea Therapeutics

In other news, Director Bernd R. Seizinger bought 6,860 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The stock was acquired at an average cost of $7.29 per share, with a total value of $50,009.40. Following the transaction, the director now directly owns 33,685 shares of the company’s stock, valued at approximately $245,563.65. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders bought 9,870 shares of company stock valued at $71,952 in the last three months. Corporate insiders own 20.90% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.